TUESDAY, Sept. 3 (HealthDay News) -- An injectable drug that
mimics the action of a little-known hormone may hold promise for
patients with type 2 diabetes.
The experimental drug, called LY, is a copy of a hormone called
fibroblast growth factor 21 (FGF21), and researchers report that it
seems to help protect against obesity and may boost the action of
In a month-long trial of 46 patients with type 2 diabetes who
were randomly assigned to receive daily injections of the drug or
an inactive placebo, patients who received the highest doses of the
drug saw significant, favorable changes in their blood fat (lipid)
levels compared to those on the dummy shots. Two "bad" blood fats
-- LDL and triglycerides -- dropped, while patients' HDL, or "good"
cholesterol, increased. Total cholesterol counts also dropped
significantly compared to placebo shots.
Patients on the highest doses of the drug also lost a bit of
weight, the researchers added.
Insulin and blood sugar levels did dip a bit in patients on the
highest doses of the drug, but those changes were not statistically
significant compared to patients who were taking the placebo shots,
which means they could simply have been a coincidence.
Still, the study authors said they were hopeful that the drug
may one day become a useful addition to currently available
"Our current understanding suggests that FGF21 has the ability to favorably affect body weight, partially normalize abnormal lipid levels in patients with diabetes, and has the potential to improve glycemic control," said senior study author Dr. Dave Moller, vice president of endocrinology and cardiovascular research, and clinical investigation for Eli Lilly Co., the company that's developing the drug.
"These are substantial issues and unmet medical needs for patients with obesity and type 2 diabetes," he added.
The study is published in the Sept. 3 issue of the journal
An endocrinologist who was not involved in the research said the
effects of the experimental medication were intriguing.
"There are some interesting properties here that longer studies and bigger numbers will need to confirm," said Dr. Ronald Goldberg, a professor of medicine in the Diabetes Research Institute at the University of Miami's Miller School of Medicine. "This is early days for this new medication."
Goldberg said a longer study would be needed to see if the
changes in blood fat levels and weight amounted to real benefits
for patients with diabetes, such as a reduction in heart attacks or
other complications of the disease.
So far, other drugs that raise good cholesterol and lower
triglycerides have not demonstrated real benefits for patients.
And side effects could be a concern. Even though the study was
short, there were some signs that the medication might not be
well-tolerated, the report indicated.
One patient on the highest dose of the drug developed a serious
allergic reaction to the medication including a drop in blood
pressure, itching and hives, and had to be treated with
corticosteroids and antihistamines.
While no other serious allergic reactions were reported, more
than 80 percent of patients on the two highest doses of the drug
developed antibodies to the protein, a sign that their body
recognized the drug as foreign and was mounting an immune reaction
against it, something that might diminish the effectiveness of the
medication over time.
"That's definitely an issue," Goldberg said, adding that he thought scientists would probably try to tweak the drug to make it less likely to spur immune reactions.
For more on cholesterol and diabetes, visit the
American Heart Association.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.